glioma

News

Servier bags FDA okay for glioma drug from $2bn Agios buy

The FDA has approved Servier's vorasidenib for two forms of glioma, becoming the first targeted therapy for this aggressive and incurable form of brain cancer.

News

Ipsen builds again, licensing Day One glioma drug

Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceutical

News

NICE backs Novartis duo for NHS use in young glioma patients

An oral therapy that can allow children and adolescents with an aggressive form of brain cancer to be treated at home rather than in hospital has been recommended for use

News

US, EU regulators start swift reviews of Servier glioma drug

The US FDA and EMA in the EU have started accelerated reviews of Servier’s vorasidenib for IDH-mutated low-grade glioma, which is vying to become the first targeted therapy for this a

News

ASCO: Vorasidenib shows its glioma potential in INDIGO

Servier’s vorasidenib has shown efficacy in the treatment of low-grade glioma – a notoriously hard-to-treat form of brain cancer – although safety data has taken some of t

News